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Abstract 
Chemotherapy-resistant cancer stem cells (CSCs) are a major obstacle to the effective treatment 
of many forms of cancer. To overcome CSC chemo-resistance, we developed a novel system by 
conjugating a CSC-targeting EpCAM aptamer with doxorubicin (Apt-DOX) to eliminate CSCs. 
Incubation of Apt-DOX with colorectal cancer cells resulted in high concentration and prolonged 
retention of DOX in the nuclei. Treatment of tumour-bearing xenograft mice with Apt-DOX 
resulted in at least 3-fold more inhibition of tumour growth and longer survival as well as a 30-fold 
lower frequency of CSC and a prolonged longer tumourigenic latency compared with those 
receiving the same dose of free DOX. Our data demonstrate that a CSC-targeting aptamer is able 
to transform a conventional chemotherapeutic agent into a CSC-killer to overcome drug 
resistance in solid tumours. 
Key words: doxorubicin, cancer stem cell killer 
Introduction 
Current approaches including chemotherapy 
and radiotherapy are widely used for cancer 
treatment, but their lack of specificity to cancer cells 
often results in increased side effects and limited 
therapeutic efficacy1, 2. The dose-limiting toxicity of 
free drugs used in clinic limits the possibility to treat a 
patient at a planned dose or to timely start a new cycle 
of treatment, thereby underlying the failure of 
chemotherapy3, 4. The current failure of cancer 
treatment is largely attributed to our inability in 
eradicating cancer stem cells (CSCs)5, 6. In the CSC 
model, only a small population of cancer cells possess 
the ability to extensively proliferate, self-renew, 
differentiate to multiple lineages and generate a 
tumour5, 7. CSCs, as ‘roots of cancer’, are defined by 
their abilities to form new tumours that histologically 
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resembles the original tumour when transplanted into 
immunodeficient mice; they are resistant to 
traditional therapies such as chemo- and/or 
radio-therapy8-10. As CSCs are more drug resistant, 
more aggressive, and more invasive with higher 
metastatic potential than their non-CSC counterparts, 
this population of cells must be effectively targeted in 
order to improve the survival of patients with cancer5.  
To achieve this goal, tumour active targeting 
systems have been intensively explored as they have 
the tumour-targeting potential to deliver therapeutic 
agents more selectively to cancer cells, thereby 
enhancing the therapeutic efficacy while minimizing 
non-specific toxicity to healthy cells 11, 12. Active 
targeting entails the guidance of therapeutic agents, 
with the aid of targeting ligands, to tumour cells and 
promotes their subsequent cellular entry through 
receptor-mediated endocytosis 13-15. Aptamers, as 
chemical antibodies, are novel ligands for drug 
targeting and offer significant advantages over 
antibodies in terms of smaller size, low 
immunogenicity and high stability, as well as the high 
reproducibility and ease for chemical 
modification16-19.  
Currently, there is no approved agent on the 
market that is able to effectively eliminate CSCs. 
Instead of developing new drugs to target CSCs, this 
study aimed to explore a novel strategy that utilizes a 
CSC-targeting moiety to deliver existing 
chemotherapeutic agents to target CSCs. Aptamers, 
also known as chemical antibodies, are 
single-stranded DNA or RNA molecules that could 
specifically bind their targets with high affinity and 
specificity 20, 21, which have been broadly applied for 
targeted cancer therapy 22-24. We have developed two 
RNA aptamers against CSC surface markers (EpCAM 
and CD133) 25, 26. Doxorubicin (DOX) is widely used 
for treating a spectrum of cancers including 
hematological malignancies and solid cancers of 
breast, ovarian, lung and others. DOX functions by 
intercalating double-stranded G-C sequences of DNA 
and inhibits the synthesis of nuclei acids, resulting in 
DNA damage, epigenome and transcriptome 
deregulation 27. However, the dose-limiting toxicity of 
DOX has limited its success in anticancer treatment 
due to non-specific targeting and increased 
emergence of drug resistance 27. By directly 
conjugating DOX to a CSC-targeting EpCAM aptamer 
without any chemical modification of the drug, we 
reasoned that this strategy may be able to effectively 
target EpCAM-expressing CSCs followed via 
enhanced cellular internalization and delivery the 
drug to the nuclei of CSCs. To test this hypothesis, a 
colorectal cancer mouse xenograft model using HT29 
cells was established and a set of in vitro, ex vivo and in 
vivo studies were conducted to evaluate the potential 
of the CSC-targeted aptamer-mediated active 
targeting as a promising strategy for effective 
eradicating CSCs. 
Results  
pH-dependent release of DOX from 
aptamer-drug complex 
We have previously developed and optimized 
an 18-nt RNA aptamer (18-nucleotides) against a CSC 
marker EpCAM 25, 26. To target a traditional anticancer 
agent, doxorubicin (DOX), to CSCs, we developed a 
self-assembled and CSC-targeted drug conjugate. As 
our work previously demonstrated that it is the loop 
of this RNA aptamer that determines its target 
binding and the modifications made to the stem 
portion of the aptamer have no discernible impact on 
target interaction 25, 26, we engineered the stem of the 
EpCAM aptamer (Fig. 1A). As DOX binds to RNA 
poorly, the stem of the original RNA aptamer was 
replaced with a 10-bp DNA G-C stem. In addition, 
5’-methyl-deoxycytidine (dC) was deployed in the 
newly engineered DNA stem to achieve increased 
duplex stability and reduced immunogenicity. Next, a 
self-assembled Apt-DOX conjugate was created by 
conjugation of DOX with chemically modified 
DNA-RNA hybrid EpCAM aptamer27. The images of 
atomic force microscopy (AFM) showed the 
morphologies of the corresponding nanostructures of 
aptamer and the conjugation of aptamer and DOX 
(Fig. 1B and Supplementary Fig. 1A). We observed the 
formation of two different adsorbed nanostructures, 
which indicated molecular interaction of DOX to the 
aptamer using atomic force microscopy (AFM). An 
aptamer, which has a 2’-O-methyl (2’-O-Me) instead 
of 2’-fluoropyrimidine modifications in the loop of the 
RNA was used as a negative control throughout the 
study as it does not bind to EpCAM 25, 26.  
The optimal molar ratio for DOX loading into the 
aptamer was determined to be 0.4 (~2.5 molecules 
DOX assembled per aptamer) at which the quenching 
of the DOX fluorescence reached a plateau around 
92% (Fig. 1C and Supplementary Fig. 1B). As shown 
in Fig. 1D, less than 18% of DOX was released from 
both Apt-DOX and control Apt-DOX (Ctrl-Apt-DOX) 
after 8 h in PBS buffer (pH 7.4), indicating a high 
stability of the Apt-DOX complex under physiological 
pH when transiting in the blood. We have previously 
shown that upon binding to cell surface EpCAM, the 
EpCAM aptamers are internalized via endocytosis 28. 
As the lysosomes are the end subcellular location for 
cargos entering the cells via endocytosis and they 
have a pH of approximately 5.0, we next studied the 
pH-dependent release of DOX from the engineered 
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EpCAM aptamer at pH 5.0, pH 7.4 and pH 8.0 at 37 
°C. As shown in Fig. 1E, there was an initial burst of 
DOX release at pH 5.0 followed by a steady and 
continued release at acidic conditions (pH 5.0), with a 
3.1-fold to 4.8-fold increase of DOX release from 
Apt-DOX conjugates compared with that in the 
neutral or slightly basic conditions. Specifically, 
approximately 89.2 % of the intercalated DOX was 
released after 72 h at pH 5.0, while only 27.6 % and 
18.4 % of the DOX were released from the engineered 
aptamer after 72 h at pH 7.4 and pH 8.0, respectively. 
Such a pH-dependent drug release is desirable as it 
could minimize the systemic exposure of DOX to 
sensitive organs under physiological conditions (pH 
7.4), but allow a swift release of DOX from the 
Apt-DOX complex after endocytosis 29.  
Time- and dose-dependent delivery leads to 
enhanced on-target retention 
Next, we examined the effect of the conjugation 
of DOX to EpCAM aptamer on binding affinity and 
specificity of the aptamer to target EpCAM proteins. 
As shown in Fig. 2A and Supplementary Fig. 2A, the 
EpCAM Apt-DOX conjugate displayed negligible 
binding to the EpCAM-negative HEK293T cells (with 
an apparent K’d of >1000 nM); while it bound to 
EpCAM-positive HT29 cells with a K’d being 16.08 ± 
4.83 nM (Supplementary Fig. 2B). The improved 
binding affinity of Apt-DOX conjugate over the free 
aptamer could be attributed to a more stable 3-D 
structure of the Apt-DOX conferred by the 10-bp GC 
stem and the conjugation of the DOX. The specificity 
of such interaction was further demonstrated by the 
lack of binding to target cells by a negative 
Ctrl-Apt-DOX that had an identical nucleotide 
sequence but an altered 3-D structure due to a 
different chemical modification at 2’-pyrimidines that 
abolishes its binding to EpCAM (Supplementary Fig. 
2A). The ability of the Apt-DOX conjugate to 
successfully undergo endocytosis into 
EpCAM-positive but not in EpCAM–negative target 
cells was confirmed using a 3-D culture model via 
confocal microscopy (Fig. 2A). 
We next sought to evaluate whether EpCAM 
Apt-DOX enters target cells in a time- and 
dose-dependent manner. In time course studies over 
either a 10-min or 30 min period, the cumulative 
cellular uptake of the Apt-DOX was found to increase 
by 2-2.5 fold compared with that of free DOX and the 
Ctrl-Apt-DOX, respectively (P < 0.01) (Fig. 2B). 
Similarly, a dose-dependent uptake of the Apt-DOX 
was observed over a dose of up to 2 µM equivalent of 
DOX (Fig. 2C). Taken together, these results suggest 
that Apt-DOX is capable of efficiently targeting HT29 
cells and enhancing the intracellular delivery of DOX 
both in a time- and dose-dependent manner. Since the 
persistence in on-target intracellular drug 
concentration is critical to its clinical efficacy, we 
further analyzed the intracellular retention of DOX as 
delivered by EpCAM aptamer. In studies involving a 
 
Figure 1. Characterization of EpCAM Apt-DOX conjugates. (A) Schematic illustration of the hybrid RNA-DNA EpCAM aptamer. (B) AFM analysis of 
intercalation between the aptamer and DOX. Based on cross section analysis, the size of aptamers were around 1.3 nm, while the conjugated structure has size of 
around 2.5 nm. (C) The fluorescence quenching of 10 μM DOX after 30 min incubation with an increasing molar ratio of aptamer-to-DOX (0.001, 0.002, 0.004, 0.006, 
0.1, 0.6 and 1). (D) Time-dependent release of DOX from aptamer conjugates at pH 7.4 in vitro. The “Free DOX” sample was used to demonstrate the ability of the 
DOX dissociated from the aptamer can cross the membrane of the dialysis device. (E) pH-dependent release of DOX from aptamer conjugates at pH of 5.0, 7.4 and 
8.0. Data shown are means ± SEM (n=3).  
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10 min incubation with 1.5 µM DOX or equivalent 
Apt-DOX followed by a wash-out period of 2 h, the 
HT29 cells treated with Apt-DOX retained 16.34 ng 
DOX per 1 x 106 cells, while only 0.12 ng and 4.79 ng 
DOX per 1 x 106 cells were retained in cells treated 
with free DOX and Ctrl-Apt-DOX, respectively (Fig. 
2D, left bars). Importantly, after a 24 h wash-out 
period, there was a limited residual amount of DOX 
left in cells treated with free DOX or Ctrl-Apt-DOX, 
while cells treated with Apt-DOX still retained 5.16 ng 
DOX per 1 x 106 cells. (P < 0.01) (Fig. 2D, left bars). 
Consistently, similar results were obtained in cells 
undergoing a 30 min incubation with 1.5 µM DOX or 
equivalent Apt-DOX followed by a wash-out period 
of 2 or 24 h (Fig. 2D, right bars). Next, we investigated 
if DOX was retained in the nuclei of EpCAM 
Apt-DOX treated HT29 cells using confocal 
microscopy. As shown in Fig. 2E, after incubation for 
0.5 h or 2 h, a large amount of Apt-DOX was found in 
the nuclei, evident from the overlapping of red (for 
DOX) or blue (for EpCAM aptamer) with cyan (for 
nuclei) fluorescence (Fig. 2E). After 2 h or 24 h drug 
wash-out period, the red fluorescence signal for DOX 
in the cells treated with Apt-DOX was clearly 
detectable. In contrast, little red fluorescence in the 
nuclei of the cells incubated with free DOX were 
discernable after a 2 h wash-out period (Fig. 2F and 
Supplementary Fig. 2C). Thus, delivering DOX by 
EpCAM aptamer led to an enhanced time- and 
dose-dependent cellular uptake as well as a 
significantly improved on-target DOX accumulation 
in target cells.  
Elimination of self-renewal cells by 
aptamer-guided DOX treatment both in vitro 
and ex vivo 
Having established that Apt-DOX can deliver a 
large dose of DOX into colorectal cancer cells, it is 
important to evaluate if this translates into effective 
pharmacological outcome of eliminating CSCs. To this 
end, we used a tumoursphere assay to determine the 
impact of treatment on a key feature of CSC, namely 
the self-renewal potential. Using the limiting dilution 
assay (LDA), serial dilutions of HT29 cells were 
seeded in stem cell culture conditions and incubated 
with 1 μM of free DOX or equivalent concentration of 
Apt-DOX30. Salinomycin, an agent known to be able 
to robustly kill CSCs, was used as a positive control to 
validate the sensitivity of the tumoursphere assay 
system in detecting the elimination of cells with 
self-renewal capacity 31. Cells treated with free DOX 
showed moderate decrease in the frequency of 
tumoursphere formation, especially for those with a 
cell seeding dose of 5 cells/well or less (Fig. 3A, 
Supplementary Fig. 3A and Supplementary Table 1). 
In contrast, cells treated with, aptamer targeted 
delivery of DOX (Apt-DOX) resulted in a 16.7-fold 
decrease of CSC frequency compared to that of free 
DOX (Fig. 3A). After Apt-DOX treatment, the 
percentage of tumoursphere formation in the first 
passage was found to be 8.7 % which was a 10.4-fold 
decrease than that of free DOX treated tumour cells. 
This reduction in tumoursphere formation was more 
pronounced during the second (12.37-fold lower) and 
third round (170-fold lower) of tumoursphere culture 
during which cells without true self-renewal 
capability that managed to survive the first-round 
tumoursphere assay are more effectively eliminated 
(Fig. 3B). The efficacy of aptamer targeted delivery of 
DOX in eliminating putative CSCs in the 
tumoursphere assays was confirmed in two 
additional carcinoma models, namely the ovarian 
cancer cell line SKOV-3 and the breast cancer cell line 
T47D (Supplementary Fig. 3B and Supplementary 
Table 2). Thus, these results indicate that the 
Apt-DOX treatment could effectively impair the 
tumorigenicity of CSCs in at least three types of solid 
tumours.  
To further determine if the treatment of cancer 
cells with Apt-DOX would affect the ability of CSC to 
form tumours in immunocompromised mice, HT29 
cells were treated in vitro as indicated in Fig. 3C for 5 
days and then injected subcutaneously (s.c.) into 
NOD/SCID mice at two cell doses of 1 × 105 or 1 × 104 
per site. In vitro treatment of Apt-DOX resulted in an 
approximately 3.9 × 105-fold lower CSC frequency 
than that of cells treated by free DOX in NOD/SCID 
mice (Supplementary 3C. and Supplementary Table 
3). Remarkably, no tumour was formed in 
NOD/SCID mice when 1 × 104 cells treated with 
Apt-DOX were implanted, in sharp contrast to the 
mice receiving the same dose of cells treated with free 
DOX or the saline or aptamer-only controls 
(Supplementary Fig. 3D and 3E). As for the tumour 
latency, mice that received 1 × 105 cells treated by 
Apt-DOX exhibited a significantly longer tumour-free 
period of ~6 weeks, compared to a latent period of 2 
weeks in mice that received cells treated with free 
DOX (Fig. 3C). Accordingly, the mice-bearing HT-29 
cells treated with Apt-DOX survived more than 3 
weeks longer than the mice-bearing cells treated with 
free DOX at the inoculating cell dose of 1 × 105 (Fig. 
3D). These results strongly suggest that the EpCAM 
aptamer-guided delivery of DOX successfully 
targeted and eradicated CSCs in vitro, resulting in 
suppressed tumour growth, prolonged tumour-free 
tendency and extended survival.  
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Figure 2. Specific and enhanced delivery of DOX into target cells via aptamer-guided delivery. (A) Specificity of uptake of EpCAM Apt-DOX into 
EpCAM-positive HT29 tumourspheres but not the EpCAM-negative HEK293T tumourspheres at 37 °C for 30 min. Scale bar is 10 μm. Time-dependent (B) and 
dose-dependent (C) intracellular delivery of Apt-DOX into monolayer HT29 cells. (D) Time-dependent total cellular uptake and retention of Apt-DOX (1.5 μM of 
DOX equivalent) in HT29 cells. (E-F) Time-dependent uptake and retention of DOX by Apt-DOX in the nuclei of HT29 cells after incubating cells with 1.5 μM of 
DOX or equivalent Apt-DOX at 37 °C for 30 min or 2 h, followed by washing and further 2 h or 24 h incubation with fresh medium. (E) EpCAM-Apt-DOX; (F) free 
DOX. Scale bar is 5 μm. Data shown are means ± SEM. (n=3). **P < 0.01, ***P < 0.001 compared with free DOX treatment groups (two-tailed Student’s t-test). 
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Figure 3. Impairment of CSC self-renewal function following Apt-DOX treatment in vitro and ex vivo. (A) The percent of CSC frequency of HT29 cells based on in 
vitro limiting dilution assay. (B) The percent of tumoursphere following 5-7 days incubation of HT29 cells (8 × 103) with various agents as indicated under stem cell 
culture conditions. (C) Tumour growth of colorectal tumours that were transplanted with 1 × 105 cells/mouse following treatment with various agents as indicated. 
(D) Kaplan-Meier survival curves of NOD/SCID mice bearing xenograft tumours treated with varies agents as described above. Data shown are means ± SEM. (n=3, 
unless indicated otherwise).  
 
PEGylation improves pharmaceutical profile 
and tumour delivery of Apt-DOX in vivo 
To improve the pharmaceutical profile of 
Apt-DOX, the EpCAM aptamer was further 
engineered by conjugating a terminal 20 kDa 
polyethylene glycol (PEG) to increase its blood 
retention32 and the pharmacokinetics was evaluated 
in healthy Sprague Dawley rats. Following a single 
intravenous (i.v.) injection, the DOX concentration 
was measured as shown in Fig. 4A and 
Supplementary Table 4. In contrast to a short half-life 
(t1/2: 0.87 h) for free DOX, the PEGylated Apt-DOX 
displayed much prolonged half-life of approximately 
7 h, a significantly increased the mean residence time 
(MRT) of 16.25 h compared to a MRT of 2.48 h for free 
DOX, as well as a 7-fold higher area under the curve 
(AUC) and a 10-fold lower clearance (CL). These 
results revealed that the DOX intercalated to 
PEGylated aptamer has a substantially improved 
pharmacokinetic profile than free DOX in vivo.  
To assess if the improved serum 
pharmacokinetics translates into better in vivo uptake 
of Apt-DOX in the target tissue, the biodistribution of 
DOX in various tissues were studied after a single i.v. 
injection of various agents. DOX concentration in the 
tumour in mice receiving free DOX exhibited a low 
peak concentration at 3 h followed by a steady 
decrease of DOX over the 24 h period (Fig. 4B and C). 
In contrast, during the same period, the concentration 
of DOX in the tumour of mice receiving Apt-DOX was 
100-200% higher than those receiving free DOX, 
reaching a peak concentration of DOX in tumours at 6 
h followed by a slight decline, to around 73 % of the 
peak, at 24 h after administration (Fig. 4B and C). 
Remarkably, even 24 h after the administration of 
Apt-DOX, the DOX concentration in the tumour was 
still 22% higher than that at 3 h after administration 
(Fig. 4C). Interestingly, the levels of DOX in the heart, 
the site of principal dose-liming toxicity of DOX, of 
the tumour-bearing mice receiving Apt-DOX 
treatment were 39% to 70% lower than those treated 
with free DOX at all three time points studied (Fig. 
4D). To investigate whether the PEGylated Apt-DOX 
could reduce side effects of DOX, changes in body 
weights of mice-bearing xenograft tumours were 
monitored after treatments. HT29 tumour-bearing 
 Theranostics 2017, Vol. 7, Issue 17 
 
 
http://www.thno.org 
4077 
mice receiving free DOX treatment lost 5.7-fold more 
weight than those treated with pegylated Apt-DOX (P 
< 0.01), while tumour-bearing mice receiving free 
aptamer and saline displayed an increase in body 
weight (Supplementary Fig. 4). Taken together, the 
aptamer-guided delivery of DOX not only improved 
DOX accumulation in tumours, but also enhanced the 
safety profile, with reduced cardiac exposure.  
Improved antitumour efficacy afforded by 
Apt-DOX 
Given that aptamer-guided DOX delivery could 
efficiently impair CSC’s self-renewal function in vitro, 
we next studied the antitumour efficacy of Apt-DOX 
in HT-29 colorectal xenografts in NOD/SCID mice. 
Treatment of s.c. tumour-bearing mice with Apt-DOX 
resulted in a significantly reduced rate of tumour 
growth with an 8-fold and 3-fold smaller tumour size 
compared with the mice receiving saline or free DOX 
treatment, respectively (P < 0.01) (Fig. 5A). Mice 
receiving free DOX or negative control Apt-DOX 
succumbed to the tumours at day 51, while those 
treated with Apt-DOX had a remarkably prolonged 
survival beyond day 63 (Fig. 5B). Therefore, the 
aptamer-guided DOX delivery could effectively target 
CSCs in vivo and thus significantly inhibited the 
tumour growth and extended overall survival of the 
tumour-bearing mice. 
The progression of cancer is controlled by the 
rate of cancer cell proliferation and apoptosis 33. We 
next sought to evaluate the effects of Apt-DOX 
treatment on apoptosis and the proliferation of HT29 
xenograft tumour cells. As shown in Fig. 5C, while 
single treatment with DOX alone induced limited 
apoptosis in tumours, Apt-DOX treatment elicited a 
9.3-fold and 3.75-fold increase in apoptotic tumour 
cells compared with that in saline- and free 
DOX-treatment groups, respectively (Fig. 5C and 
Supplementary Fig. 5A). These data indicate that the 
major inhibition of tumour growth was at least partly 
due to the increased apoptosis effect induced by 
Apt-DOX. Similarly, a Ki-67 index observed in 
tumours treated with Apt-DOX was significantly 
reduced (~6-fold decrease) compared to tumours 
treated with free DOX or Ctrl-Apt-DOX (Fig. 5D and 
Supplementary Fig. 5B), indicating that the 
aptamer-guided DOX treatment not only strongly 
promoted apoptosis but also inhibited the 
proliferation of tumour cells.  
 
 
Figure 4. Pharmaceutical profile and biodistribution of PEGylated Apt-DOX. (A) Pharmacokinetic profiles of DOX after a single i.v. injection of free DOX, 
PEGylated Apt-DOX and control PEGylated Apt-DOX conjugate into SD rats at an equivalent dosage of 5 mg/kg DOX followed by quantification of DOX in blood 
plasma. (B) Biodistribution profiles of DOX accumulation in tumour and organs 24 h after i.v. injection of agents at an equivalent dosage of 5 mg/mL DOX. (C-D) 
Biodistribution of DOX in the tumour (C) and heart (D), 24 h after i.v. injection. Data shown are means ± SEM. (n=3, unless indicated otherwise). *P < 0.05, **P < 
0.01 compared with free DOX administration groups (two-tailed Student’s t-test).  
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Figure 5. Apt-DOX treatment enhanced apoptosis and inhibited cell proliferation in HT29 xenograft tumour. NOD/SCID mice bearing HT29 
xenograft tumours with a volume of 50 mm3 were treated with agents as indicated. (A-B) Aptamer-guided DOX delivery inhibited tumour growth and extended 
survival rate of mice-bearing HT29 tumours. NOD/SCID mice-bearing HT29 xenograft tumour were randomized into six groups and treated as described in the 
legend. (A) The change of the tumour volume over 63 days (n=4). (B) Kaplan-Meier survival curves of mice (n=4) bearing HT29 tumour treated as indicated. (C) 
Quantification of apoptotic cells in the treated xenograft tumours using TUNEL assay. (D) Quantification of Ki-67 positive cells in HT29 xenograft tumours treated 
as indicated. Data shown are means ± SEM. (n=3, unless indicated otherwise). ** P < 0.01 compared with mice receiving free DOX (two-tailed Student’s t-test). 
 
Diminished tumorigenicity of colorectal CSCs 
treated with Apt-DOX 
To assess the impact of Apt-DOX treatment on 
the self-renewal capacities of CSCs in vivo, an in vitro 
tumoursphere initiation with LDA was carried out on 
single cell suspensions prepared from xenograft 
tumours after in vivo treatment. As shown in 
Supplementary Table 5, there was a 207.8- and 
18.1-fold decrease in the frequency of sphere 
re-initiating cells from tumour-bearing mice treated 
with Apt-DOX compared to those treated with saline 
and free DOX, respectively. To verify the in vivo 
efficacy of Apt-DOX in targeting CSCs, the 
self-renewal capacity of CSCs from the treated 
xenograft tumours was studied using the secondary 
in vivo tumour initiation assays at serial limiting cell 
doses34-36. To this end, single cell suspensions 
prepared from the tumours removed from the mice 
treated by various agents were re-implanted into 
naïve NOD/SCID mice s.c. at cell doses of 1 × 105, 1 × 
104, 1 × 103 and 1 × 102/site. At the inoculating cell 
dose of 1 × 103, tumours formed in all mice receiving 
cells treated with free drug or a control 
(Supplementary Table 6). In contrast, no tumour was 
detected in mice receiving 1 × 103 cells dissociated 
from the mice treated with Apt-DOX after 3 months, 
suggesting that Apt-DOX conjugate treatment 
eliminated most, if not all, CSCs at this cell dose. 
Implantation of 1 × 104 cells treated by Apt-DOX 
exhibited a significantly longer tumour-free period 
than those receiving free DOX (7 weeks vs 4 weeks) 
(Supplementary Table 6). At higher inoculating cell 
doses of 1 × 105, there were a ~20 days longer 
tumour-free period in mice that received Apt-DOX 
than those treated with free DOX. There was a 30-fold 
reduction in the frequency of self-renewing CSCs in 
naïve mice receiving tumour cells from mice that had 
been treated with Apt-DOX compared with those that 
received tumour cells from mice treated with free 
DOX (P < 0.0001) (Supplementary Table 6). Thus, 
DOX, a classic anti-cancer drug, has been transformed 
into a new agent that effectively eliminates CSCs 
when it is delivered by the EpCAM aptamer.  
To evaluate the in vivo CSC-targeting capability 
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of Apt-DOX, direct evidence on eliminating of CSCs 
was sought through experiments conducted directly 
on the putative colorectal CSCs isolated from 
xenograft HT29 tumours that had undergone various 
treatments in vivo (Fig. 6). It was previously shown by 
others that CSC population in HT29 tumours can be 
defined using a set of cell surface markers 
EpCAM+CD24+CD44+.37, 38 Thus, we first determined 
the binding and internalization of the Apt-DOX in 
FACS-sorted populations of EpCAM+CD24+CD44+ 
CSCs and EpCAM-CD44-CD24- non-CSCs from the 
xenograft tumours. The confocal microscopy 
confirmed that DY647-labelled Apt-DOX was indeed 
internalized into colorectal CSCs (Fig. 6A). No 
DY647-labelled Apt-DOX was found in 
EpCAM-CD44-CD24- cells. Second, approximately 24 
h after the last treatment, the intracellular 
concentration of DOX delivered by Apt-DOX in 
EpCAM+CD24+CD44+ cells was found to be 1.5-fold 
higher than that in mice receiving free DOX (P = 
0.031) (Fig. 6B). Third, 78% of EpCAM+CD24+CD44+ 
cells from mice treated with Apt-DOX were found to 
be apoptotic (TUNEL positive), in sharp contrast to 
~19% apoptotic cells in the EpCAM+CD24+CD44+ cells 
isolated from tumours treated with free DOX s (P < 
0.0001) (Fig. 6C and Supplementary 6A). Therefore, 
the Apt-DOX is able to target CSCs in HT29 xenograft 
tumour in vivo. 
 
 
Figure 6. Impairment of CSC self-renewal capability in xenograft tumours following Apt-DOX treatment in vivo. (A-C) Apt-DOX was delivered 
into EpCAM+/CD44+/CD24+ cells in treated xenograft tumours and eliminated CSCs. (A) Representative micrographs showing efficient targeting of Apt-DOX to 
EpCAM+CD24+CD44+ cells in HT29 xenograft tumours. Scale bar is 10 μm. (B) Retention of DOX in FACS-sorted EpCAM+CD24+CD44+ cells in xenograft tumours 
after indicated treatments. The tumour-bearing animals were euthanized 3 h after the last treatment. (C) Quantification of apoptotic EpCAM+CD24+CD44+ cells 
after various treatments using TUNEL assay (n=4). Data shown are means ± SEM. (n=3, unless indicated otherwise). P value was obtained by the two-tailed Student’s 
t-test.  
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Discussion 
Current anticancer strategies that mainly focus 
on eliminating the bulk cancer cells fail to cure cancers 
as the remaining population of CSCs may cause 
tumour recurrence regarding their treatment 
resistance, aggressiveness and metastatic potential 39. 
EpCAM is expressed at low levels in normal epithelial 
cells, but its expression is 800~1000-fold higher in 
cancer cells 20, 21, 40. EpCAM is considered as a stem cell 
marker in multiple solid tumours, including colon, 
breast, pancreas, liver, and prostate tumours; and 
tumour cells with high EpCAM expression have been 
shown to correlate with CSC’s phenotype and 
properties 25, 26, 41, 42. Therefore, EpCAM is a valid 
target for CSC-targeted therapy. Here the RNA 
EpCAM aptamer was utilized to develop a novel 
therapeutic strategy to transform a traditional 
chemotherapeutic drug into an agent for eradicating 
CSCs. 
Despite DOX being a robust anticancer drug that 
is able to kill the majority of rapidly proliferating cells 
in cancer, abundant preclinical and clinical studies 
have revealed that DOX is largely ineffective in 
eliminating CSCs 43-46. Furthermore, the clinical 
applications of DOX are often associated with the 
emergence of drug resistance and enrichment of CSCs 
47-51. Here an RNA aptamer was engineered with a 
binding loop specific to EpCAM and a docking DNA 
stem for loading DOX 52, 53. The retention of DOX with 
the aptamer during transit at neutral pH and the 
release of DOX at acidic pH are critical to the success 
of targeted cancer therapy. Indeed, the payload (DOX) 
is largely retained within the Apt-DOX conjugate at 
pH of 7.4, but released efficiently at pH 5.0 (Fig. 1D, 
E). These data suggest that DOX would remain stably 
conjugated with the EpCAM aptamer in the 
circulatory system and tissue interstitium, but be 
released from the aptamer following intracellular 
delivery in the endosome-lysosome compartment. 
This allows DOX to mainly exert its cytotoxic effect 
after entering the target cells, enhancing the 
therapeutic index of the Apt-DOX conjugate.  
Furthermore, this pH-dependent intracellular release 
of DOX from the Apt-DOX complex could circumvent 
the efflux by ABC transporters, allowing delivery of 
the DOX to the site of action, the nucleus. Indeed, 
confocal microscopy revealed that the treatment with 
Apt-DOX resulted in a more effective accumulation 
and retention of DOX in the nuclei compared with 
free DOX (Fig. 2E-F). Such data also suggest that free 
DOX is rapidly effluxed after entering cells via 
random diffusion, while DOX delivered by Apt-DOX 
could circumvent the highly elevated drug efflux 
systems in cancer cells.  
The gold standard approach to study CSCs is to 
xenotransplant tumour cells into immunodeficient 
mice with LDA followed by evaluating functions of 
putative CSCs. Here, an in vitro surrogate of the gold 
standard CSC assay, tumoursphere formation assay, 
was employed to provide initial assessment of the 
CSC-targeting ability of Apt-DOX conjugates as it 
allows us to functionally test a key property of CSCs, 
self-renewal. Careful analysis at serial seeding doses 
of cells confirmed the ability of Apt-DOX conjugates 
in inhibiting sphere-initiating frequency (Fig. 3A and 
B, Supplementary Table 1). In addition to the 
colorectal cancer HT29 cells, two additional cancer 
cell lines from different types of solid tumour (ovarian 
and breast cancers) were also studied (Fig. 
Supplementary 3B, and Supplementary Table 2). The 
results indicated that the aptamer-guided DOX 
delivery to EpCAM-overexpressing cells could be a 
universal approach for CSC-targeted therapy. To 
functionally verify the CSC-targeting ability of 
Apt-DOX, an ex vivo LDA was conducted by 
xenotransplanting single cell suspensions from cells 
previously treated with Apt-DOX or controls in vitro 
into NOD/SCID mice. Consistent with the in vitro 
results from tumoursphere assays, the treatment of 
cells with Apt-DOX resulted in a significant reduction 
of tumour growth and a longer latency, compared to 
those treated with free DOX or other negative controls 
(Fig. 3C, Supplementary 3C and Supplementary Table 
3). Most importantly, the Apt-DOX treatment 
remarkably prolonged the survival of mice-bearing 
HT29 tumours, indicating that the subpopulation of 
CSCs was effectively eliminated, at least partially, in 
vitro before they were xenotransplanted into mice 
(Fig. 3D, Supplementary 3D). Thus, targeted in vivo 
delivery of DOX leads to the elimination of cancer 
stem cells in the xenograft tumour mouse model 
studied. 
Cytotoxic chemotherapy remains the corner 
stone of the first-line therapy for many advanced solid 
tumours. However, chemoresistance often develops 
and up to 90% of patients with metastatic cancer 
eventually succumb to the disease 54. Vast preclinical 
studies and clinical data suggest that when 
administrated in the current fashion, 
chemotherapeutic drugs, such as DOX, are unable to 
eliminate CSCs in most cases 55. A widely held view in 
the field is that CSCs are intrinsically resistant to 
chemotherapeutic agents. Therefore, heroic efforts 
have been devoted to develop next generation 
inhibitors to pathways leading to chemoresistance 56. 
However, the data presented in this study suggest 
that resistance to chemotherapeutic agents, such as 
DOX, might not be the consequence of the 
dysregulation of various molecular and cellular 
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pathways currently being attributed to 
chemoresistance in CSC. Rather, the failure of 
chemotherapy in eliminating CSCs in the clinics could 
be due to our inability to fulfill a fundamental 
pharmacological and pharmaceutical principle: one 
needs to deliver a sufficient dose to the 
pharmacological subcellular location for sufficient 
time in order to kill a target cell. Our data 
demonstrate for the first time that as long as one can 
deliver sufficient amount of DOX to the nuclei of 
target cells for a sufficient period of time, the 
Aptamer-DOX, but not the free DOX administered at 
the same concentration/dose, can indeed eliminate 
CSCs both in vitro and in vivo. Furthermore, our 
results indicate that CSCs, as studied in our model, 
are actually intrinsically sensitive to DOX. Given the 
recent strong doubt casted on the feasibility, 
cost-effectiveness and the clinical success of 
precision-oncology 57, our findings suggest a new 
paradigm in cancer drug development in which one 
can utilize the current chemotherapeutic agents that 
we have extensive knowledge on their 
pharmacological and toxicological properties to 
develop novel delivery strategies in order to 
overcome chemoresistance. Considering the lengthy 
and costly road of developing a new drug, the smart 
delivery of existing anti-cancer drugs is indeed a very 
attractive alternative to combating cancer.  
Over the past 2 decades, many drug delivery 
systems have been developed for doxorubicin58. In 
fact, the first US Food and Drug Administration 
approved nano-drug is Doxil®, a PEGylated 
nano-liposomal formulation of doxorubicin 59. More 
recently, efforts were devoted to develop targeted 
drug delivery system for doxorubicin 58. Some 
ingenious systems developed include a chemically 
crosslinked and functionalized biopolymer dextrin 
based nanogel 60; an anti-CD24 mAb–DOX conjugate 
via the non-cleavable GMBS (N-[gamma-maleic imide 
butyl acyl oxygen] succinimide ester) linker 61; a metal 
organic framework nanocarrier-based codelivery 
system functionalized with folic acid 62; a urokinase 
plasminogen activator receptor targeted magnetic 
iron oxide nanoparticles 63; a double-targeted 
nondrug delivery system via conjugating hyaluronic 
acid and grafting the doublecortin-like kinase 1 
monoclonal antibody to the surface of PEG-PLGA 
nanoparticles 64; a nucleolin-binding F3 peptide 
functionalized liposome 65; a pH-sensitive triblock 
copolymer vesicles functionalized with EpCAM 
monoclonal antibodies 66; hyaluronic acid functional 
amphipathic and redox-responsive polymer particles 
with a redox-responsive drug release profile 67; 
EpCAM aptamer conjugated PEG-PLGA 
nanopolymersomes as well as direct aptamer-DOX 
conjugates 23, 68, 69. These innovations have 
significantly improved the pharmacokinetics and 
curtailed toxicity of doxorubicin in the preclinical 
experimental systems employed. In addition, these 
studies have also demonstrated markedly improve 
pharmacodynamics to the general population of 
cancer cells. However, it is unclear whether these 
DOX delivery systems can turn doxorubicin into a 
cancer stem cell killer. One cannot be ascertained if a 
DOX-delivery system is able to eliminate cancer stem 
cell that in the absence of the experimental data using 
the gold standard methodology for enumeration of 
cancer stem cell frequency via the limiting dilution 
transplantation analysis using immunodeficient mice 
70, 71. In this contribution, we have provided evidence 
that our aptamer-DOX system can indeed physically 
deliver DOX into EpCAM+/CD44+/CD24+ colorectal 
cancer stem cells in the HT29 tumour xenograft mice 
model (Figure 6 A) and eliminate such cancer stem 
cells via apoptosis, which is a well know mode of 
action by DOX. Most critically, by employing the gold 
standard CSC functional assay via limiting dilution 
combined with xenotransplantation, we have 
provided unequivocal evidence that our EpCAM 
aptamer can indeed turn DOX into a robust cancer 
stem cell killer (Supplementary  Figure 3, 
Supplementary Table 1, Supplementary Table 2, 
Supplementary Table 3, Supplementary Table 5 and 
Supplementary Table 6). Therefore, for the first time, 
we have demonstrated that one can indeed transform 
a traditional anti-cancer drug into a potent cancer 
stem cell killer via smart drug delivery without the 
use of nanoparticles. Such a CSC-busting system will 
facilitate the effective treatment of the disseminated 
cancer cells that are largely responsible for the death 
of patients with cancer 72. 
In summary, an EpCAM-aptamer-based delivery 
system has been developed to target CSCs. The high 
concentration and prolonged retention of DOX 
delivered by Apt-DOX to the nuclei significantly 
improved the sensitivity of CSCs to DOX, leading to 
overcoming chemoresistance and elimination of CSCs 
both in vitro and in vivo. This novel strategy of drug 
delivery opens a new avenue for overcoming 
chemoresistance by transforming traditional 
chemotherapeutic agents into CSC killers. Further 
testing of this innovative approach in clinical trials 
will provide fresh insight into how to overcome 
chemoresistant cancers. 
Materials and Methods  
Cell lines and cell culture 
Human colorectal adenocarcinoma cell line 
HT-29 (ATCC®, HTB38™), human ovarian 
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adenocarcinoma cell lines SKOV-3 (ATCC®, 
HTB77™), and human embryonic kidney cell 
HEK-293T (ATCC®, CRL-11268™), and human 
hepatocellular carcinoma cell lines Huh-7 and 
PLC/PRF/7 (gift from Dr. Liang Qiao, University of 
Sydney, Australia) were cultured in DMEM medium 
supplemented with 10% fetal bovine serum (FBS), 
10,000 I.U./mL Penicillin, 50 µg/ml streptomycin 
(Invitrogen, Australia) and 1× Glutamax (Life 
Technologies, Australia) in a humidified atmosphere 
containing 5% CO2 at 37 °C.  
Animals used in this study 
All animals were purchased from The Animal 
Resources Centre (Perth, Australia). Six to eight weeks 
old NOD-SCID female mice were used for HT29 
tumour xenograft establishment. The mice were 
housed in TECNIPLAST SealsafeTM individually 
ventilated cages. Both mice and Male 
Sprague-Dawley rats (200 to 250 g) were placed in a 
temperature-controlled room (25 ± 1 °C) with a 12-h 
light-dark cycle and fed ad libitum with a standard 
diet. Rats were fasted overnight before treatments 
administration. Tumour progression was monitored 
using digital calipers. All experiments were 
performed in accordance with the Australian Code of 
Practice for the Care and Use of Animals for Scientific 
Purposes and Guidelines to Promote the Wellbeing of 
Animals Used for Scientific Purposes from Australian 
Government’s National Health and Medical Research 
Council. The Deakin University Animal Ethics 
Committee approved all experimental protocols. 
Aptamers used in this study 
Aptamers were synthesized by IBA GmbH 
(Göttingen, Germany) followed by HPLC 
purification. The aptamers used in this study were, 
RNA EpCAM aptamer [5’- (DY647) - A (2’-F-C) G 
(2’-F-U) A (2’-F-U) (2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) 
(2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) G (2’-F-U) 
-3’], negative control RNA EpCAM aptamer [5’- 
(DY647) - A (2’-O-Me-C) G (2’-O-Me-U) A 
(2’-O-Me-U) (2’-O-Me-C) (2’-O-Me-C) (2’-O-Me-C) 
(2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) 
(2’-O-Me-C) G (2’-O-Me-C) G (2’-O-Me-U) -3’], hybrid 
DNA-RNA EpCAM aptamer [5’- (DY647) - c g c g c g c 
c g c A (2’-F-C) G (2’-F-U) A (2’-F-U) (2’-F-C) (2’-F-C) 
(2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G 
(2’-F-C) G (2’-F-U) c g g c g c g c g -3’], negative control 
Hybrid DNA-RNA EpCAM aptamer [5’- (DY647) - c g 
c g c g c c g c A (2’-O-Me-C) G (2’-O-Me-U) A 
(2’-O-Me-U) (2’-O-Me-C) (2’-O-Me-C) (2’-O-Me-C) 
(2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) 
(2’-O-Me-C) G (2’-O-Me-C) G (2’-O-Me-U) c g g c g c g 
c g -3’], PEGylated RNA EpCAM aptamer [5’-(20 kDa 
PEG-FITC)- c g c g c g c c g c A (2’-F-C) G (2’-F-U) A 
(2’-F-U) (2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) 
(2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) G (2’-F-U) c g g c g 
c g c g - (Biotin or DY647) -3’], negative control 
PEGylated RNA EpCAM aptamer: 5’-(20 kDa 
PEG-FITC)- c g c g c g c c g c A (2’-O-Me-C) G 
(2’-O-Me-U) A (2’-O-Me-U) (2’-O-Me-C) (2’-O-Me-C) 
(2’-O-Me-C) (2’-O-Me-U) (2’-O-Me-U) (2’-O-Me-U) 
(2’-O-Me-U) (2’-O-Me-C) G (2’-O-Me-C) G 
(2’-O-Me-U) c g g c g c g c g - (Biotin or DY647) -3’],  
In the above sequences, 2’-F represents 
2’-fluoropyrimidine, 2’-O-Me indicates 2’-O-methyl 
modification. The lowercase letters indicate DNAs in 
which deoxycytidines were modified with 
5’-methyl-deoxycytidine (5-Methyl-dC), which 
increases the Tm by as much as 0.5°C per limits 
unwanted immune responses 73, 74. The negative 
control aptamer is an aptamer of the same sequence as 
the EpCAM targeting aptamer but with a 2’-O-methyl 
modification at the pyrimidines that changes the 
3-dimensional structure of aptamer and thus 
abolishing the binding of this control aptamer to 
EpCAM. The aptamers were folded in PBS containing 
5 mM MgCl2, by denaturation at 85˚C for 5 min, 
followed by 10 min incubation at room temperature 
and refolding at 37˚C for at least 15 min. 
Development of aptamer-drug conjugate 
EpCAM aptamer was designed for conjugation 
with doxorubicin (DOX) (SIGMA-ALDRICH). DOX 
was mixed with folded aptamer in conjugation buffer 
containing 0.1 M sodium acetate, 0.05 M NaCl, and 5 
mM MgCl2, pH 7.4 and incubated in orbital 
mixer/incubator at 37 °C for 1 hour at 75 r.p.m. The 
conjugate mixture was then passed through a 
Sephadex®G-10 medium column (SIGMA-ALDRICH) 
to separate the Apt-DOX from free DOX. DOX was 
quantified as follows. Apt-DOX conjugate (30 µL) was 
added into 90 µL of acetonitrile and vortex for 1 min, 
followed by centrifugation for 5 min at 21,000 x g. The 
supernatant (50 μL) was diluted in 150 µL PBS and 
mixed well prior to another centrifugation for 5 min at 
21,000 g. Sixty to one hundred micro-liters of 
supernatant was analyzed in a fluorescence 
VICTORTM X5 Plate Reader (PerkinElmer Life, 
Australia) at an excitation and emission wavelength 
of 470 nm and 585 nm, respectively. A standard curve 
of free DOX was also prepared in parallel.  
Evaluation of DOX conjugation with aptamer 
The natural fluorescence of DOX and its 
subsequent quenching after intercalating into the 
aptamer allows efficient quantification of DOX. 
Fluorescence intensity in solutions with different 
aptamer to DOX molar ratios (0, 0.01, 0.02, 0.04, 0.08, 
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0.1, 0.2, 0.4, 0.6, and 1) were measured using a 
VICTORTM X5 plate reader (PerkinElmer Life) at ex. 
480 nm and em. 575 nm or by HPLC,) and compared 
with a standard curve of free DOX solution prepared 
in parallel. The efficient loading of DOX into aptamers 
was determined with a fixed concentration of DOX 
incubated with increasing amount of aptamer at a 
wavelength from 520 nm to 700 nm.  
Determination of the stability of Apt-DOX 
conjugates 
The release of DOX from Apt-DOX conjugates in 
vitro were studied by monitoring the release of DOX 
from the conjugates using a dialysis method with a 
Slide-A-Lyzer Dialysis Cassette (ThermoFisher 
Scientific). For determination of the stability, 
aptamer-DOX conjugates at an equivalent DOX 
concentration of 1µg/mL were dialysed against 
conjugation buffer at 37 °C. At various time points, (10 
min, 0.5 h, 1 h, 2h, 4 h, 6 h, 8 h, 24 h, 26 h, 30 h, 32 h, 48 
h, 50 h, 54 h and 72 h), 400 µL of each sample outside 
the dialysis cassette were collected the concentration 
of free DOX in the dialysis buffer was determined. 
Accumulative release of DOX from Apt-DOX was 
expressed as a percentage of the released DOX vs 
time. 
Determination of binding affinity 
The equilibrium dissociation constant (K’d) of 
2’-F RNA aptamer species to EpCAM proteins 
expressed on the cell surface was determined using 
flow cytometry as described in our previous 
publication75.  
Cellular uptake and retention of Apt-DOX. 
Cells were seeded at a density of 75,000 cells per 
cm2 in an 8-chamber slide (Lab-Tek II, Nunc) and 
incubated in blocking buffer (PBS supplemented with 
5 mM MgCl2, 0.1 mg/mL tRNA, 0.1 mg⁄mL salmon 
sperm DNA, and 5% FBS) at room temperature for 20 
min. After two washes with PBS, cells were cultured 
in full DMEM medium (phenol red free) for another 2 
h with 50 nM LysoTracker (Life Technologies) in the 
first 90 min, followed by the incubation with 100 nM 
folded EpCAM aptamer or 100 nM FITC-EpCAM 
antibody for 30 min. Cells were then counterstained 
with 3 ng/mLHoechst 33342 (Sigma). Images were 
analysed using Image-Pro software (Media 
Cybernetics).  
To determine the internalization of Apt-DOX, 
cells were prepared and blocked as described above 
prior to incubation with free DOX and Apt-DOX at an 
equivalent DOX concentration of 1.5 µM for 30 min 
and 2 h at 37˚C, (time course)followed by 
counterstaining with Hoechst 33342. At each time 
point, solution of DOX or aptamer-DOX conjugates 
was removed and the cells washed three times prior 
to visualization via confocal microscopy. As for 
evaluating the retention of Apt-DOX within tumour 
cells, HT-29 tumour cells were incubated with phenol 
red-free DMEM for a further 2 h and 24 h before being 
imaged. The co-localization of DOX in nucleus was 
quantified using Image-Pro software. 
To quantitatively determine the accumulation of 
Apt-DOX inside cancer cells, cellular uptake and 
retention of Apt-DOX compared to that of free DOX 
was determined. After 10 and 30 min incubation of 
HT29 sphere cells with free DOX, Apt-DOX and 
Ctrl-Apt-DOX (at an equivalent concentration of 1.5 
µM DOX), cells were washed with PBS and incubated 
with phenol red-free media red for a further 2 and 24 
h, respectively.The dose-dependent analysis was 
performed by incubating cells with DOX and 
aptamer-DOX at concentrations equivalent to 0.5, 1 
and 2 µM DOX. Untreated cells were used as a 
control. 
Analysis of tumoursphere penetration of 
Apt-DOX 
Two thousand HT29 and HEK293T cells were 
plated out in ultralow attachment wells (Corning, 
Germany) and allowed to form tumourspheres for 3-5 
days in stem cell media (DMEM/F12 media 
supplemented with B27 (100 units/mL), Insulin (10 
µg/mL), EGF (20 ng/mL) and bFGF (20 ng/mL). 
After being washed three times in PBS containing 5 
mM MgCl2 and blocked for 20 min using blocking 
buffer, the tumourspheres were then incubated with 
100 nM of Apt-DOX for 30 min followed by three 
washes with PBS prior to visualization using confocal 
microscopy. 
Tumour implantation and evaluation 
To establish xenograft tumours, single HT29 cell 
suspension was harvested after trypsinization. The 
cells (1 × 105) resuspended in DMEM and Matrigel 
(50:50 = V:V) were injected into the flank of 
NOD/SCID mouse. Once tumours arose, mice were 
randomized into treatment groups of 4 mice per 
group. Treatment was initiated when the tumour 
volume reached 150 mm3. Tumour fragments were 
archived in 10% neutral buffered formalin and 
subjected to immunohistochemistry analysis (double 
staining of anti-CD31 and aptamer or antibody). 
Chromatographic instrumentation and system 
A high performance liquid chromatography 
(HPLC) system consisting of a Waters e2695 
Separation Module and a Waters 2475 Multi λ 
Fluorescence Detector was used with the excitation 
and emission wavelengths being 470 nm and 585 nm, 
respectively. Chromatographic separation was 
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performed using a Nova-Pak® C18 column (3.9 × 150 
mm i.d., 4 μm, Waters, USA) using the 
chromatographic process described previously 76. 
Pharmacokinetics (PK) study 
Healthy male Sprague-Dawley rats (200 to 250 g, 
n=3) were injected i.v. with agents at an equivalent 
dose of DOX 5 mg/kg. After injection, blood was 
serially collected from animals tail vein into 
heparinised tubes from the tail vein at the time points 
of 10 min, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 
h and 24 h. Blood samples (200 μL) were centrifuged 
at 3,000 g at 4 °C for 10 min to separate the plasma. 
The supernatant was stored at -20 °C until 
determination of DOX by HPLC. The 
pharmacokinetic parameters were analysed using the 
DAS 2.0 software (Mathematical Pharmacology 
Professional Committee of China). 
Bio-distribution assay 
HT29 tumour (an average volume of 150 
mm3)-bearing NOD/SCID mice were randomly 
divided into three treatment groups as above with 3 
mice per group. Agents were delivered via tail vein 
injection with an equivalent dose of DOX 5 mg/kg. 
Tissues and tumours were collected 3 h, 6h and 24 h 
post treatments. The concentration of DOX was 
determined using HPLC77 while the aptamer 
concentration was quantified by aptamer-ELISA78. 
Tumour dissociation 
HT29 xenograft tumour tissues were washed 
thoroughly with Hank’s buffer (containing 1% 
penicillin/strep), and minced into approximately 2 - 4 
mm3 followed by additional three washes in Hank’s 
buffer. The minced tissues were digested with 50-100 
U/mL collagenase in stem cell media, with a medium 
to tissue ratio of 6 mL/gram at 37 °C for 3 h for cell 
sorting or overnight for replating. The samples were 
then pipetted 10 times and filtered through 40 µm cell 
strainers. Cells were collected through centrifugation 
at 1000 g for 5 min, resuspended and washed in PBS 
twice followed by cell viability assay using Trypan 
blue staining.  
Fluorescence-activated cell sorting 
Cells were analysed using FACS-Canto II or 
sorted using the FACSAria flow cytometer as 
described in our previous publication78. The 
antibodies used were: human-specific antibodies to 
PE-CD24 (1:25 dilution, BD Biosciences, Cat. No: 
555428), V450-CD44 (1:100 dilution, BD Biosciences, 
Cat. No: 561292) and FITC-EpCAM (1:10 dilution) (BD 
Biosciences, Cat No: 347197). Cells were routinely 
sorted twice, and an aliquot of sorted the cells (1 × 105) 
was reanalyzed for purity, which typically was > 95%. 
For surface marker analysis, a minimum of 10,000 
events were analysed for each sample from three 
independent experiments.  
Tumoursphere formation and ex vivo 
tumorigenicity assays 
The colonosphere assay was conducted 
according to previously reported protocols 79. Briefly, 
cells were harvested at 80% confluence with trypsin 
digestion and resuspended as single cells in stem cell 
medium. Cells were plated into round-bottom 96-well 
ultralow attachment plates (Corning) at a density of 1, 
5, 10, 100, and 200 cells per well, or at 8000 cells /well 
in 6-well flat-bottom ultralow attachment plates. Six 
experiment groups were used: saline, free aptamer, 
free DOX treatment (1 µM), Ctrl-Apt-DOX and 
Apt-DOX treatment (equivalent to 1 µM free DOX) 
and salinomycin (1 µM). The frequency of CSCs was 
calculated using the ELDA website 
(http://bioinf.wehi.edu.au/software/elda/index.ht
ml). The tumoursphere formation frequency in 6-well 
plates was calculated according to the formula F= 
Numbers of forming tumourspheres / Number of 
single cells plated. For secondary and tertiary 
tumoursphere formation, single cell suspension 
prepared from the previous generation of 
tumourspheres were re-plated under the same 
conditions as the first generation.  
For LDA, HT29 cells were cultured in ultra-low 
attachment plate and maintained in stem cell 
medium. Following 5 - 7 days of treatment with free 
Aptamer, free DOX and Apt-DOX (2 µM), single cell 
preparation of HT29 sphere-forming cells were 
injected subcutaneously (s.c.) into NOD/SCID mice at 
a dose of 1x 104 and 1 x 105 in serum-free 
DMEM/Matrigel (V:V = 1:1). Tumour volume was 
monitored and calculated as described77.  
In vivo tumorigenicity assay 
HT29 tumour-bearing NOD/SCID mice (60 
mm3) were randomly assigned to six groups (n=4) 
and received i.v. injection of agents indicated. One 
day after the last treatment, viable single cell 
suspensions dissociated from each tumour were 
inoculated into four sub-groups of mice using cell 
doses of 1 × 105, 1 × 104, 1 × 103 and 1 × 102/mouse, 4 
mice per sub-group. The growth of tumour was 
evaluated daily over a 3-month period. The animal 
ethics endpoint was tumour reaching a size of 17 mm 
or the loss of 10% weight. The CSC frequency was 
derived as described above. 
Immunohistochemistry 
The tumour tissues dissected from 
tumour-bearing mice were subjected to 
immunohistochemistry analysis using methods 
 Theranostics 2017, Vol. 7, Issue 17 
 
 
http://www.thno.org 
4085 
described in our previous publication 80. The 
antibodies used include mouse anti-human Ki-67 
antibody (Abcam, Cat No: ab15580, 1:100 dilution) 
and goat anti-mouse HRP-labelled secondary 
antibody (Thermo Fisher, Cat No: 31430) as well as 
DAB peroxidase substrate solution (Vector 
Laboratories, Burlingame, CA). For performing the 
TUNEL assay, the indicated slides were performed 
using the ApopTag Red In Situ Apoptosis Detection 
Kit (Millipore) according to the manufactural 
instruction.  
Evaluation of antitumour efficacy and survival 
rate 
HT29 tumour (50 mm3) bearing mice were 
grouped and treated using the same method as that 
for in vivo tumorigenicity assay. The mice were 
evaluated daily for disease-free survival and 
disease-related events. The Kaplan-Meier Survival 
Curves were derived using a Log-Rank test with a 
95% confidence interval.  
Statistical analysis 
All statistical analyses were performed using 
GraphPad Prism 6.0 (San Diego, CA, USA). An 
unpaired t test was used for comparisons between 
two experimental groups, and ANOVA was used for 
comparisons of more than two groups. Unless 
otherwise indicated, all results were averaged from 
biological triplicates and values are reported as means 
± SEM. P < 0.05 was considered statistically 
significant. 
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